نتائج البحث - Vaibhav Sahai

تنقيح النتائج
  1. 1
    Statistical medium optimization and production of a hyperthermostable lipase from Burkholderia cepacia in a bioreactor

    Statistical medium optimization and production of a hyperthermostable lipase from Burkholderia cepacia in a bioreactor حسب Pooja Rathi, Vineet Kumar Goswami, Vaibhav Sahai, Rani Gupta

    منشور في 2002
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  2. 2
    Epidermal Growth Factor Receptor Expression and Gene Copy Number in Conventional Hepatocellular Carcinoma

    Epidermal Growth Factor Receptor Expression and Gene Copy Number in Conventional Hepatocellular Carcinoma حسب Anne F. Buckley, Lawrence J. Burgart, Vaibhav Sahai, Sanjay Kakar

    منشور في 2008
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  3. 3
    Opportunities and Challenges for Pancreatic Circulating Tumor Cells

    Opportunities and Challenges for Pancreatic Circulating Tumor Cells حسب Sunitha Nagrath, Rhonda M. Jack, Vaibhav Sahai, Diane M. Simeone

    منشور في 2016
    احصل على النص الكامل احصل على النص الكامل
    Revisão
    أضف إلى المفضلة
    محفوظ في:
  4. 4
    Three-Dimensional Collagen I Promotes Gemcitabine Resistance In Vitro in Pancreatic Cancer Cells through HMGA2-Dependent Histone Acetyltransferase Expression

    Three-Dimensional Collagen I Promotes Gemcitabine Resistance In Vitro in Pancreatic Cancer Cells through HMGA2-Dependent Histone Acetyltransferase Expression حسب Surabhi Dangi‐Garimella, Vaibhav Sahai, Kazumi Ebine, Krishan Kumar, Hidayatullah G. Munshi

    منشور في 2013
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  5. 5
    Loss of heterozygosity, aberrant methylation, BRAF mutation and KRAS mutation in colorectal signet ring cell carcinoma

    Loss of heterozygosity, aberrant methylation, BRAF mutation and KRAS mutation in colorectal signet ring cell carcinoma حسب Sanjay Kakar, Guoren Deng, Thomas C. Smyrk, Lisa Cun, Vaibhav Sahai, Young S. Kim

    منشور في 2012
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  6. 6
    Targeting BET bromodomain proteins in solid tumors

    Targeting BET bromodomain proteins in solid tumors حسب Vaibhav Sahai, Amanda J. Redig, Katharine A. Collier, Frank Eckerdt, Hidayatullah G. Munshi

    منشور في 2016
    احصل على النص الكامل احصل على النص الكامل
    Revisão
    أضف إلى المفضلة
    محفوظ في:
  7. 7
    Clinical Benefits of Above-Standard Dose of Octreotide LAR in Patients With Neuroendocrine Tumors for Control of Carcinoid Syndrome Symptoms: A Multicenter Retrospective Chart Review Study

    Clinical Benefits of Above-Standard Dose of Octreotide LAR in Patients With Neuroendocrine Tumors for Control of Carcinoid Syndrome Symptoms: A Multicenter Retrospective Chart Revi... حسب Jonathan Strosberg, Al B. Benson, Lynn Huynh, Mei Sheng Duh, Jamie Goldman, Vaibhav Sahai, Alfred Rademaker, Matthew H. Kulke

    منشور في 2014
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  8. 8
    BET Bromodomain Inhibitors Block Growth of Pancreatic Cancer Cells in Three-Dimensional Collagen

    BET Bromodomain Inhibitors Block Growth of Pancreatic Cancer Cells in Three-Dimensional Collagen حسب Vaibhav Sahai, Krishan Kumar, Lawrence M. Knab, Christina R. Chow, Sania S. Raza, David J. Bentrem, Kazumi Ebine, Hidayatullah G. Munshi

    منشور في 2014
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  9. 9
    Snail Cooperates with KrasG12D to Promote Pancreatic Fibrosis

    Snail Cooperates with KrasG12D to Promote Pancreatic Fibrosis حسب Mario A. Shields, Kazumi Ebine, Vaibhav Sahai, Krishan Kumar, Kulsumjehan Siddiqui, Rosa F. Hwang, Paul J. Grippo, Hidayatullah G. Munshi

    منشور في 2013
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  10. 10
    A randomized phase 2 trial of nivolumab, gemcitabine, and cisplatin or nivolumab and ipilimumab in previously untreated advanced biliary cancer: <scp>BilT</scp>‐01

    A randomized phase 2 trial of nivolumab, gemcitabine, and cisplatin or nivolumab and ipilimumab in previously untreated advanced biliary cancer: <scp>BilT</scp>‐01 حسب Vaibhav Sahai, Kent A. Griffith, Muhammad S. Beg, Walid L. Shaib, Devalingam Mahalingam, David B. Zhen, Dustin A. Deming, Mark M. Zalupski

    منشور في 2022
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  11. 11
    P-286 Metronomic 5-fluorouracil (5-FU) plus nab-paclitaxel (nab-P), bevacizumab, leucovorin, and oxaliplatin (FABLOx) in patients with metastatic pancreatic cancer (MPC): an open-label, multicenter, single-arm, phase 1/2 study

    P-286 Metronomic 5-fluorouracil (5-FU) plus nab-paclitaxel (nab-P), bevacizumab, leucovorin, and oxaliplatin (FABLOx) in patients with metastatic pancreatic cancer (MPC): an open-l... حسب Vincent, Picozzi, Caio, Rocha Lima, Vaibhav, Sahai, Diane, Simeone, Allyson, Ocean, Philip, Philip, Wasif, Saif, Aparna, Kalyan, Michael, Ondovik, Jack, Shiansong Li, Victoria, Manax

    منشور في 2016
    احصل على النص الكامل احصل على النص الكامل
    نص
    أضف إلى المفضلة
    محفوظ في:
  12. 12
    Nab-Paclitaxel and Gemcitabine as First-line Treatment of Advanced or Metastatic Cholangiocarcinoma

    Nab-Paclitaxel and Gemcitabine as First-line Treatment of Advanced or Metastatic Cholangiocarcinoma حسب Vaibhav Sahai, Paul J. Catalano, Mark M. Zalupski, Sam Joseph Lubner, Mark R. Menge, Halla Nimeiri, Hidayatullah G. Munshi, Al B. Benson, Peter J. O’Dwyer

    منشور في 2018
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  13. 13
    Deep immune profiling of intrahepatic cholangiocarcinoma with CODEX multiplexed imaging

    Deep immune profiling of intrahepatic cholangiocarcinoma with CODEX multiplexed imaging حسب Marina Baretti, Soumya Shekhar, Vaibhav Sahai, Daniel Shu, Kathryn L. Howe, Valerie Gunchick, Naziheh Assarzadegan, Emma Kartalia, Qingfeng Zhu, Elsa Hallab, Archit Sheth-Shah, Aya Kondo, Nilofer S. Azad, Mark Yarchoan

    منشور في 2025
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  14. 14
    Pilot Clinical Trial of Hedgehog Pathway Inhibitor GDC-0449 (Vismodegib) in Combination with Gemcitabine in Patients with Metastatic Pancreatic Adenocarcinoma

    Pilot Clinical Trial of Hedgehog Pathway Inhibitor GDC-0449 (Vismodegib) in Combination with Gemcitabine in Patients with Metastatic Pancreatic Adenocarcinoma حسب Edward Kim, Vaibhav Sahai, Ethan V. Abel, Kent A. Griffith, Joel K. Greenson, Naoko Takebe, Gazala Khan, John Blau, Ronald A. Craig, Ulysses J. Balis, Mark M. Zalupski, Diane M. Simeone

    منشور في 2014
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  15. 15
    ATM-deficiency increases genomic instability and metastatic potential in a mouse model of pancreatic cancer

    ATM-deficiency increases genomic instability and metastatic potential in a mouse model of pancreatic cancer حسب Yiannis Drosos, David Escobar, Ming-Yi Chiang, Kathryn Roys, Virginia Valentine, Marc Valentine, Jerold E. Rehg, Vaibhav Sahai, Lesa Begley, Jianming Ye, Leena Paul, Peter J. McKinnon, Beatriz Sosa‐Pineda

    منشور في 2017
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  16. 16
    Dose Escalation Trial of the Wee1 Inhibitor Adavosertib (AZD1775) in Combination With Gemcitabine and Radiation for Patients With Locally Advanced Pancreatic Cancer

    Dose Escalation Trial of the Wee1 Inhibitor Adavosertib (AZD1775) in Combination With Gemcitabine and Radiation for Patients With Locally Advanced Pancreatic Cancer حسب Kyle C. Cuneo, Meredith A. Morgan, Vaibhav Sahai, Matthew J. Schipper, Leslie A. Parsels, Joshua D. Parsels, Theresa P. Devasia, Mahmoud Al-Hawaray, Clifford S. Cho, Hari Nathan, Jonathan Maybaum, Mark M. Zalupski, Theodore S. Lawrence

    منشور في 2019
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  17. 17
    Randomised phase II trial (SWOG S1310) of single agent MEK inhibitor trametinib Versus 5-fluorouracil or capecitabine in refractory advanced biliary cancer

    Randomised phase II trial (SWOG S1310) of single agent MEK inhibitor trametinib Versus 5-fluorouracil or capecitabine in refractory advanced biliary cancer حسب Richard D. Kim, Shannon McDonough, Anthony B. El-Khoueiry, Tanios Bekaii‐Saab, Stacey Stein, Vaibhav Sahai, George P. Keogh, Edward Kim, Ari David Baron, Abby B. Siegel, Afsaneh Barzi, Katherine A. Guthrie, Milind Javle, Howard S. Höchster

    منشور في 2020
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  18. 18
    GM-CSF Mediates Mesenchymal–Epithelial Cross-talk in Pancreatic Cancer

    GM-CSF Mediates Mesenchymal–Epithelial Cross-talk in Pancreatic Cancer حسب Meghna Waghray, Malica Yalamanchili, Michele Dziubinski, Mina Zeinali, Marguerite Erkkinen, Huibin Yang, Kara A. Schradle, Sumithra Urs, Marina Pasca di Magliano, Theodore H. Welling, Phillip L. Palmbos, Ethan V. Abel, Vaibhav Sahai, Sunitha Nagrath, Lidong Wang, Diane M. Simeone

    منشور في 2016
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  19. 19
    Overall survival in patients with pancreatic cancer receiving matched therapies following molecular profiling: a retrospective analysis of the Know Your Tumor registry trial

    Overall survival in patients with pancreatic cancer receiving matched therapies following molecular profiling: a retrospective analysis of the Know Your Tumor registry trial حسب Michael J. Pishvaian, Edik M. Blais, Jonathan R. Brody, Emily E. Lyons, Patricia DeArbeloa, Andrew Hendifar, Sam Mikhail, Vincent Chung, Vaibhav Sahai, Davendra Sohal, Sara Bellakbira, Dzung Thach, Lola Rahib, Subha Madhavan, Lynn M. Matrisian, Emanuel F. Petricoin

    منشور في 2020
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  20. 20
    Devimistat in Combination with Gemcitabine and Cisplatin in Biliary Tract Cancer: Preclinical Evaluation and Phase Ib Multicenter Clinical Trial (BilT-04)

    Devimistat in Combination with Gemcitabine and Cisplatin in Biliary Tract Cancer: Preclinical Evaluation and Phase Ib Multicenter Clinical Trial (BilT-04) حسب Arathi Mohan, Kent A. Griffith, Fulei Wuchu, David B. Zhen, Chandan Kumar‐Sinha, Oxana Crysler, David Hsiehchen, Thomas Enzler, Dominique Dippman, Valerie Gunchick, Abhinav Achreja, Olamide Animasahun, Srinadh Choppara, Minal Nenwani, Arul M. Chinnaiyan, Deepak Nagrath, Mark M. Zalupski, Vaibhav Sahai

    منشور في 2023
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:

أدوات البحث: